Focused On-demand Library for Peroxidasin homolog

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q92626

UPID:

PXDN_HUMAN

Alternative names:

Melanoma-associated antigen MG50; Peroxidasin 1; Vascular peroxidase 1; p53-responsive gene 2 protein

Alternative UPACC:

Q92626; A8QM65; D6W4Y0; Q4KMG2

Background:

Peroxidasin homolog, also known as Melanoma-associated antigen MG50, Vascular peroxidase 1, and p53-responsive gene 2 protein, plays a pivotal role in the formation of sulfilimine cross-links between methionine and hydroxylysine within collagen IV. This process is crucial for extracellular matrix (ECM) integrity, supporting fibronectin and laminin assembly, and facilitating growth factor-induced cell proliferation and survival in endothelial cells. Its enzymatic activity, catalyzing the oxidation of bromide to hypobromite, is essential for angiogenesis and tubulogenesis.

Therapeutic significance:

Given its involvement in Anterior segment dysgenesis 7, a condition affecting eye development, understanding the role of Peroxidasin homolog could open doors to potential therapeutic strategies. Its function in ECM integrity and angiogenesis highlights its potential as a target in treating diseases related to vascular and basement membrane dysfunctions.